Regenetech Achieves a 60-Fold Increase of Adult Stem Cells Through Its cellXpansion(TM) Process



    HOUSTON, October 16 /CNW/ - Regenetech, Inc., the adult stem cell company
which has built upon NASA licensed technology, announced that the Company has
significantly augmented its cell multiplication capabilities for CD34+38-
peripheral blood progenitor cells (adult stem cells). These new results were
achieved through the continued development of cell culture conditions for
Regenetech's proprietary and patented Intrifuge(TM) cellXpansion(TM)
technology. Developing a significant and reliable technology for adult stem
cell growth and multiplication currently represents one of the most
significant barriers preventing more widespread autologous adult stem cell
therapeutic use.

    Under the new, improved growth conditions, the number of adult stem cells
increased by 50-200 times the original number, an achievement accomplished in
as few as 6 days. Compared to other serum-free media, the optimized Regenetech
formulation yields considerably higher cell numbers than were previously
achievable, significantly enhancing the market competitiveness and commercial
potential of the cellXpansion(TM) technology.

    David Bonner, CEO of Regenetech, said: "We are delighted with the
progress that the team has made. This is a significant step forward for our
technology, and we are excited about what it will allow us to do in the future
in terms of providing doses of adult stem cells to help patients. This
development will demonstrate to the wider industry that adult stem cells can
be expanded in three-dimensional conditions to achieve therapeutic doses for
autologous use. We believe this technology will have a significant impact on
many treatments and will bring us even closer to realizing the potential for
treating diseases through the use of expanded adult stem cells."

    Regenetech's technology uses NASA based technologies which were
discovered in space experiments in which adult stem cells and tissue are grown
in a weightless three-dimensional environment. The stem cells are harvested
from the patient's own blood and multiplied in Regenetech's Intrifuge(TM)
Bioreactor in order to achieve therapeutic quantities for re-introduction into
the original patient. The technology is capable of producing therapeutic
quantities of adult stem cells rapidly and at reasonable cost. Regenetech is
licensing the technology broadly to ensure the technology is available for
general use by researchers and commercial operators.

    For more information about Regenetech, contact twang@regenetech.com or
visit www.regenetech.com. For licensing opportunities, contact
rclark@regenetech.com.

    Forward Looking Statements: The Private Securities Litigation Reform Act
of 1995 provides a "safe harbor" for certain forward-looking statements.




For further information:

For further information: Regenetech, Inc. Timmie Wang, 713-838-5277
twang@regenetech.com

Organization Profile

REGENETECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890